John H. Tatlock
Pfizer (United States)(US)
Publications by Year
Research Areas
Signaling Pathways in Disease, Peptidase Inhibition and Analysis, Biochemical and Molecular Research, HIV Research and Treatment, HIV/AIDS drug development and treatment
Most-Cited Works
- → Viracept (Nelfinavir Mesylate, AG1343): A Potent, Orally Bioavailable Inhibitor of HIV-1 Protease(1997)619 cited
- → ( R )-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells(2014)187 cited
- → SETD7 Controls Intestinal Regeneration and Tumorigenesis by Regulating Wnt/β-Catenin and Hippo/YAP Signaling(2016)108 cited
- → Structure-Based Design of Novel, Urea-Containing FKBP12 Inhibitors(1996)61 cited
- → Symmetric Arginine Dimethylation Is Selectively Required for mRNA Splicing and the Initiation of Type I and Type III Interferon Signaling(2020)42 cited
- → Structure-based design of novel calcineurin (PP2B) inhibitors(1997)37 cited
- → Oxidation of Alkynyl Ethers with Potassium Permanganate. A New Acyl Anion Equivalent for the Preparation of .alpha.-Keto Esters(1995)34 cited
- → Structure-based drug design of nonpeptidic P2 substituents for HIV-1 protease inhibitors(1995)25 cited
- → Design, synthesis and X-ray crystallographic studies of [7.3.1] and [8.3.1] macrocyclic FKBP-12 ligands(1996)11 cited
- → High-affinity FKBP-12 ligands derived from (R)-(−)-carvone. Synthesis and evaluation of FK506 pyranose ring replacements(1995)10 cited